Kay B, Rolly G
Acta Anaesthesiol Belg. 1977;28(4):317-22.
I.C.I. 35868 is a promising new intravenous induction agent, but intravenous injection of the initial 2% formulation frequently caused pain. The solvent vehicle of the 2% formulation, which contained Cremophor E.L. and ethanol, was therefore investigated to see if this could be the cause of the pain. Twenty volunteers received both 5 ml isotonic saline and 5 ml solvent vehicle intravenously. The injection of saline never caused pain, but the solvent caused mild or moderate pain in 9 patients. I.C.I. 35868 was therefore reformulated in a 1% solution, excluding ethanol from the solvent. When intravenous injection of I.C.I. 35868 1% was compared to methohexitone 1% in 24 patients, both agents caused pain. Four out of 12 patients reveiving I.C.I. 35868 1% felt pain, with a total pain "score" of 6, but 6 out of 12 patients who received methohexitone 1%, felt pain, with a total pain "score" of 12. In no instance was intravenous injection followed by persistant pain, or evidence of thrombosis or phlebitis.
ICI 35868是一种很有前景的新型静脉诱导剂，但静脉注射初始的2%制剂时经常会引起疼痛。因此，对含有聚氧乙烯蓖麻油（Cremophor E.L.）和乙醇的2%制剂的溶剂载体进行了研究，以确定这是否是疼痛的原因。20名志愿者分别静脉注射了5毫升等渗盐水和5毫升溶剂载体。注射盐水从未引起疼痛，但溶剂在9名患者中引起了轻度或中度疼痛。因此，ICI 35868被重新配制为1%的溶液，溶剂中不含乙醇。在24名患者中，将1%的ICI 35868静脉注射与1%的美索比妥进行比较时，两种制剂都引起了疼痛。接受1%的ICI 35868的12名患者中有4名感到疼痛，总疼痛“评分”为6，但接受1%的美索比妥的12名患者中有6名感到疼痛，总疼痛“评分”为12。静脉注射后从未出现持续性疼痛，也没有血栓形成或静脉炎的迹象。
